Cargando…

Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis

AIM: MicroRNA-21 is an oncogenic miRNA that modulates the expression of multiple cancer-related target genes. We conducted this meta-analysis to assess diagnostic role of circulating miR-21 in CRC, hoping to choose the best biomarker in CRC diagnosis. METHODS: We searched the PubMed, CNKI and WanFan...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tong, Liu, Duo, Guan, Shangwei, Dong, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877941/
https://www.ncbi.nlm.nih.gov/pubmed/33108223
http://dx.doi.org/10.1080/07853890.2020.1828617
_version_ 1783650262347415552
author Liu, Tong
Liu, Duo
Guan, Shangwei
Dong, Mei
author_facet Liu, Tong
Liu, Duo
Guan, Shangwei
Dong, Mei
author_sort Liu, Tong
collection PubMed
description AIM: MicroRNA-21 is an oncogenic miRNA that modulates the expression of multiple cancer-related target genes. We conducted this meta-analysis to assess diagnostic role of circulating miR-21 in CRC, hoping to choose the best biomarker in CRC diagnosis. METHODS: We searched the PubMed, CNKI and WanFang database to identify records related to diagnostic role of circulating miR-21 in CRC. The search words were “microRNA-21”, “miRNA-21”, “colorectal cancer”, “colorectal carcinoma” and “diagnosis”. The searched articles were published before 14(th) July 2020. RESULTS: We got 18 studies to conduct this meta-analysis including 1129 blood specimens of CRC patients and 951 control specimens. The meta-analysis showed that the pooled sensitivity and specificity of circulating miR-21 for CRC diagnosis were 77% (95% CI, 70–82) and 83% (95% CI, 78–88). The combined positive likelihood ratio (PLR) was 4.20 (95% CI, 3.12–5.66) and the combined negative likelihood ratio(NLR) was 0.30 (95% CI, 0.23–0.38). The diagnostic odds ratio (DOR) was 16.48 (95% CI 10.09–26.91) and the area under the summary receiver operating characteristic curve (SROC) for the included studies was 0.87(95%CI, 0.84–0.90). CONCLUSION: Our meta-analysis results suggest that circulating miR-21 has a potential diagnostic value with moderate sensitivity and good specificity for CRC.
format Online
Article
Text
id pubmed-7877941
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78779412021-03-11 Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis Liu, Tong Liu, Duo Guan, Shangwei Dong, Mei Ann Med Oncology AIM: MicroRNA-21 is an oncogenic miRNA that modulates the expression of multiple cancer-related target genes. We conducted this meta-analysis to assess diagnostic role of circulating miR-21 in CRC, hoping to choose the best biomarker in CRC diagnosis. METHODS: We searched the PubMed, CNKI and WanFang database to identify records related to diagnostic role of circulating miR-21 in CRC. The search words were “microRNA-21”, “miRNA-21”, “colorectal cancer”, “colorectal carcinoma” and “diagnosis”. The searched articles were published before 14(th) July 2020. RESULTS: We got 18 studies to conduct this meta-analysis including 1129 blood specimens of CRC patients and 951 control specimens. The meta-analysis showed that the pooled sensitivity and specificity of circulating miR-21 for CRC diagnosis were 77% (95% CI, 70–82) and 83% (95% CI, 78–88). The combined positive likelihood ratio (PLR) was 4.20 (95% CI, 3.12–5.66) and the combined negative likelihood ratio(NLR) was 0.30 (95% CI, 0.23–0.38). The diagnostic odds ratio (DOR) was 16.48 (95% CI 10.09–26.91) and the area under the summary receiver operating characteristic curve (SROC) for the included studies was 0.87(95%CI, 0.84–0.90). CONCLUSION: Our meta-analysis results suggest that circulating miR-21 has a potential diagnostic value with moderate sensitivity and good specificity for CRC. Taylor & Francis 2020-10-14 /pmc/articles/PMC7877941/ /pubmed/33108223 http://dx.doi.org/10.1080/07853890.2020.1828617 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oncology
Liu, Tong
Liu, Duo
Guan, Shangwei
Dong, Mei
Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis
title Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis
title_full Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis
title_fullStr Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis
title_full_unstemmed Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis
title_short Diagnostic role of circulating MiR-21 in colorectal cancer: a update meta-analysis
title_sort diagnostic role of circulating mir-21 in colorectal cancer: a update meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877941/
https://www.ncbi.nlm.nih.gov/pubmed/33108223
http://dx.doi.org/10.1080/07853890.2020.1828617
work_keys_str_mv AT liutong diagnosticroleofcirculatingmir21incolorectalcanceraupdatemetaanalysis
AT liuduo diagnosticroleofcirculatingmir21incolorectalcanceraupdatemetaanalysis
AT guanshangwei diagnosticroleofcirculatingmir21incolorectalcanceraupdatemetaanalysis
AT dongmei diagnosticroleofcirculatingmir21incolorectalcanceraupdatemetaanalysis